Ann: Key Partnerships, page-10

We will likely start putting DurAVR into patients in January / February. With a 30 day primary end point it is not going to take very long to get some initial and final results. The results will confirm everything we know to date about our science.

Once these results come out (IMO) that is all the incumbents (and wannabe incumbents) will need to see as proof of concept for them to want a slice of the pie. Major partnership with first right of refusal or structure a take over offer.

Who knows where we will be when this eventuates in terms of share price but there is a lot of significant news to come between now and then that will be very material.

Todays move is preemptive and preparatory for what is likely to eventuate over the course of 2022.

The market will wake up eventually that Core Valve was bought by Medtronic for 900 million with a far less inferior product and significantly smaller market than currently exists and is growing rapidly. We are a 70 million MC. It’s not hard to see extreme value here.